HPV11-E6/E7与人IFNα-2b融合基因表达质粒的构建、表达与实验免疫研究
|
摘要
人类乳头瘤病毒(human papillomavirus,HPV)可在人类引起多种良恶性疾患，根据其是否诱发恶性增生性病变分为低危型和高危型。HPV6、11为低危型，为引起尖锐湿疣(condvloma accuminatum，CA)的主要HPV型别。CA在全世界发病率逐年增高，成为性传播疾病(STD)中的最常见疾病之一。在我国，CA发病人数居STD的第二位，在欧美，则已跃居第一位，严重威胁着人们的身心健康。CA目前尚没有特效治疗方法，多以去除疣体为主，但治疗后复发率高达90％以上，这已成为临床治疗中棘手的问题。
由于目前的常规手段均不能彻底治愈CA，人们开始将目光集中在HPV疫苗的研制上。然而迄今为止，HPV尚无动物模型，无法进行体外病毒培养，因此按常规方法研制HPV疫苗非常困难。随着分子生物学及基因工程的发展，人们开始运用基因克隆的方法研制DNA疫苗、蛋白疫苗和DC(dendritic cell，树突状细胞)疫苗等，其中DNA疫苗由于具有以下优点而受到人们的青睐：(1)DNA疫苗免疫应答持久、免疫效果可靠；(2)DNA疫苗可同时诱导体液免疫和细胞免疫；(3)DNA疫苗安全可靠，DNA疫苗的载体部分无免疫原性，可重复接种，不会像重组疫苗一样产生针对载体的自身免疫反
Human papillomavirus(HPV) can cause many kinds of benign and malignant diseases in human beings.According to whether inducing malignancy or not,HPVs were divided into low-risk types and high-risk types.HPV6,11 belonging to low-risks,were the main types which cause condyloma acuminatum(CA).Morbidity of CA is increasing in the world year by year and CA has become one of the most common sexually transmitted disease(STD).In our country,it becomes the second common STD,in the west,it has jumped to the top of the list and severely threatened the physical and mental health of patients.At present,there is no specific treatment for CA.In addition,recurrence rate of post-treatment is very high,which becomes a clinically formidable problem.
Up to now,HPV vaccine development and immunological study have been complicated by the lack of animal models for HPV infections and the difficulty in propagating HPVs in cultures according to the tradition. Fortunately,with the development of molecular biology and gene engineering,people began to prepare DNA vaccines,protein vaccines and DC vaccines,etc.using gene cloning .People attached more importance to DNA vaccines because their advantages are as follows: Its immunological response lasts longer and immunological result is reliable; DNA vaccines can induce humoral immunity and cellular immunity simultaneously;the vector part of DNA vaccines has no immunogenicity
由于目前的常规手段均不能彻底治愈CA，人们开始将目光集中在HPV疫苗的研制上。然而迄今为止，HPV尚无动物模型，无法进行体外病毒培养，因此按常规方法研制HPV疫苗非常困难。随着分子生物学及基因工程的发展，人们开始运用基因克隆的方法研制DNA疫苗、蛋白疫苗和DC(dendritic cell，树突状细胞)疫苗等，其中DNA疫苗由于具有以下优点而受到人们的青睐：(1)DNA疫苗免疫应答持久、免疫效果可靠；(2)DNA疫苗可同时诱导体液免疫和细胞免疫；(3)DNA疫苗安全可靠，DNA疫苗的载体部分无免疫原性，可重复接种，不会像重组疫苗一样产生针对载体的自身免疫反
Human papillomavirus(HPV) can cause many kinds of benign and malignant diseases in human beings.According to whether inducing malignancy or not,HPVs were divided into low-risk types and high-risk types.HPV6,11 belonging to low-risks,were the main types which cause condyloma acuminatum(CA).Morbidity of CA is increasing in the world year by year and CA has become one of the most common sexually transmitted disease(STD).In our country,it becomes the second common STD,in the west,it has jumped to the top of the list and severely threatened the physical and mental health of patients.At present,there is no specific treatment for CA.In addition,recurrence rate of post-treatment is very high,which becomes a clinically formidable problem.
Up to now,HPV vaccine development and immunological study have been complicated by the lack of animal models for HPV infections and the difficulty in propagating HPVs in cultures according to the tradition. Fortunately,with the development of molecular biology and gene engineering,people began to prepare DNA vaccines,protein vaccines and DC vaccines,etc.using gene cloning .People attached more importance to DNA vaccines because their advantages are as follows: Its immunological response lasts longer and immunological result is reliable; DNA vaccines can induce humoral immunity and cellular immunity simultaneously;the vector part of DNA vaccines has no immunogenicity
引文
1. Kniss DA,Rovin B,Fertel RH,et al.Blockade NF-kappaB activation prohibits TNF-alpha-induced cyclooxygenase-2 gene expression in ED27 trophoblast-like cells.Placenta,2001,22(1):80-89.
2．徐文严．STD预防与治疗．上海第二军医大学出版社，2001，23-35．
3．邵长庚．我国性病的防治状况及其对策．中华皮肤科杂志，1993，26(3)：131．
4．全国艾滋病性病防治协作组．1999年性病流行病学分析，中国性病艾滋病防治，2000，6(3)129-140．
5. Hoyme UB,Hagedorn M,Schindler AE,et al.Effect of adjuvant imiquimod 5% cream on sustained clearance of anogenital warts following laser treatment.Infect Dis Obstet Gynecol,2002,10(2): 79-88.
6．王俊杰，杨军，谢卫红等．5％咪喹莫特预防尖锐湿疣复发的临床疗效观察，临床皮肤科杂志，2005，34(6)：404．
7．金泓，邓列华，谢明等．重组人a-2b干扰素凝胶联合高频电灼术治疗尖锐湿疣临床观察．临床皮肤科杂志，2005，34(2)：124-125．
8. Stanley MA.Immunobiology of papillomavirus infections.J Reprod Immunol,2001,52(1-2) :45-59.
9. Wyllie FS,Haughton MF,Rowson JM,et al.Human thyroid cancer cells as a source of iso-genic,iso-phenotypic cell lines with or without functional p53.Br J Cancer,1999,79(7-8): 1111-1120.
10. Butz K,Whitaker N,Denk C,et al.Induction of the p53-target gene GADD45 in HPV-positive cancer cells. Oncogene,1999,18(14): 2381-2386.
11. Phillips AC,Vousden KH. Analysis of the interaction between human papillomavirus type 16 E7 and the TATA-binding protein,TBP.J Gen Virol, 1997,78 ( Pt 4):905-909.
12. Cornelison TL.Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment.Curr OpinOncol,2000, 12(5):466-473.
13. de Villiers EM.Human papillomavirus infections in skin cancers. Biomed Pharmacother, 1998,52( 1 ):26-33.
14. Yoneta A,Yamashita T,Jin HY,et al.Development of squamous cell carcinoma by two high-risk human papillomaviruses (HPVs), a novel HPV-67 and HPV-31 from bowenoid papulosis.Br J Dermatol,2000, 143(3):604-608.
15. Marshall K.Cervical dysplasia:early intervention.Altern Med Rev, 2003,8(2):156-170.
16. Munoz N,Bosch FX,de Sanjose S,et al.Epidemiologic classification of human papillomavirus types associated with cervical cancer.N Engl J Med,2003,348(6):518-527.
17. Rice PS,Mant C,Cason J,et al.High prevalence of human papillomavirus type 16 infection among children.J Med Virol,2000,61(1):70-75.
18．洪少林，王家璧，李平川．尖锐湿疣病变的人乳头瘤病毒6型L1序列多态性分析．病毒学报，2002，18(2)：102-107．
19．蒋明军，王书崎，龚向东等．尖锐湿疣皮损中人乳头瘤病毒基因分型研究．中华皮肤科杂志，2005，38(5)：262-264．
20. Bercovich JA,Centeno CR, Aguilar OG,et al.Presence and integration of human papillomavirus type 6 in a tonsillar carcinoma.J Gen Virol, 1991,72 (Pt 10):2569-2572.
21. Boshart M,zur Hausen H.Human papillomaviruses in Buschke-Lowenstein tumors: physical state of the DNA and identification of a tandem duplication in the noncoding region of a human papillomavirus6 subtype. J Virol, 1986,58(3):963-966.
22. DiLorenzo TP, Tamsen A, Abramson AL, et al.Human papillomavirus type 6a DNA in the lung carcinoma of a patient with recurrent laryngeal papillomatosis is characterized by a partial duplication.J Gen Virol,1992,73 (Pt 2):423-428.
23. Barbosa MS,Edmonds C,Fisher C,et al. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase Ⅱ phosphorylation.EMBO J, 1990,9(1): 153-160.
24. Munger K,Yee CL,Phelps WC,et al.Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences.J Virol, 1991,65(7):3943-3948.
25．白海燕，章静波．首例癌症疫苗即将面世，基础医学与临床，2005，25(3)：252．
26. O'Brien PM, Saveria Campo M.Evasion of host immunity directed by papillomavirus-encoded proteins. Virus Res,2002,88(1-2): 103-117.
27. Ferenczy A, Coutlee F, Franco E, et al.Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments. CMAJ,2003,169(5):431-434.
28. Stockfleth E,Nindl I,Sterry W, et al.Human papillomaviruses in transplant-associated skin cancers. Dermatol Surg,2004,30:604-609.
29. Chen Z,Kamath P, Zhang S,et al.Effects on tumor cells of ribozymes that cleave the RNA transcripts of human papillomavirus type 18. Cancer Gene Ther, 1996,3 (1): 18-23.
30. Clawson GA,Miranda GQ, Sivarajah A,et al.Inhibition of papilloma progression by antisense oligonucleotides targeted to HPV11 E6/E7 RNA. Gene Ther,2004,11 (17): 1331-1341.
31. Butz K, Ristriani T, Hengstermann A,et al.siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene,2003,22(38):5938-5945.
32. Oh TJ,Kim CJ,Woo SK,et al.Development and clinical evaluation of a highly sensitive DNA microarray for detection and genotyping of human papillomaviruses. J Clin Microbiol,2004,42(7):3272-3280.
33. Molijn A,Kleter B,Quint W,et al.Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol,2005,32 Suppl 1:S43-S51.
34. Meyer T,Arndt R,Christophers E,et al.Importance of human papillomaviruses for the development of skin cancer. Cancer Detect Prev,2001,25(6):533-547.
35. Ha PK,Califano JA.The role of human papillomavirus in oral carcinogenesis.Crit Rev Oral Biol Med,2004,15(4): 188-196.
36. Bouda M, Gorgoulis VG, Kastrinakis NG, et al. "High risk" HPV types are frequently detected in potentially malignant and malignant oral lesions, but not in normal oral mucosa. Mod Pathol,2000,13:644-653.
37. Brandsma JL,Abramson AL. Association of papillomavirus with cancers of the head and neck.Arch Otolaryngol Head Neck Surg, 1989,115:621-625.
38. Dreau D,Culberson C,Wyatt S,et al.Human papilloma virus in melanoma biopsy specimens and its relation to melanoma progression. Ann Surg,2000,231(5):664-671.
39. Favre M,Orth G, Majewski S,et al.Psoriasis:A possible reservoir for human papillomavirus type 5, the virus associated with skin carcinomas of epidermodysplasia verruciformis. J Invest Dermatol, 1998,110(4):311-317.
40. Handsfield HH.Clinical presentation and natural course of anogenital warts.Am J Med, 1997,102(5A): 16-20.
41. Fierlbeck G,Schiebel U, Muller C.Immunohistology of genital warts in different stages of regression after therapy with interferon gamma.Dermatologica, 1989,179(4): 191-195.
42. Ling M,Kanayama M,Roden R,et al.Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers.J Biomed Sci,2000,7(5):341-356.
43．刘方，王家璧．人乳头瘤病毒疫苗研究的新进展，中国艾滋病性病，2003，9(3)：182-184．
44. Fierlbeck G, Breuninger H,Fierlbeck B,et al.Condylomata acuminatatopical and systemic interferon therapy.Hautarzt, 1991,42(1):39-43.
45. Berry JM,Palefsky JM.A review of human papillomavirus vaccines: from basic science to clinical trials. Front Biosci,2003,8:s333-345.
46. Frazer I.Vaccines for papillomavirus infection.Virus Res,2002,89(2): 271-274.
47. Tobery TW,Smith JF, Kuklin N,et al.Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cellmediated immune responses in immunized rhesus macaques. Vaccine,2003,21 (13-14): 1539-1547.
48. Meschede W,Zumbach K,Braspenning J,et al.Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer.J Clin Microbiol, 1998,36(2):475-480.
49．党育平，王刚，范雪莉等．人乳头瘤病毒6型E7与结核杆菌热休克蛋白70融合基因的构建及原核表达．临床皮肤科杂志，2005，34(4)：208-210．
50. De Bruijn ML,Greenstone HL,Vermeulen H,et,al.L1-specific protection from tumor challenge elicited by HPV16 virus-like particles.Virology, 1998,250(2):371-376.
51. Sarkar AK,Tortolero-Luna G,Nehete PN,et al.Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16.Viral Immunol, 1995,8(3): 165-174.
52．骆卫峰，韩立群，任皎，等．人乳头瘤病毒16型E6和E7基因及其突变体转化活性的研究．病毒学报，2002，18：97-101．
53. Steller MA.Cervical cancer vaccines:progress and prospects.J Soc Gynecol Investig,2002,9(5):254-264.
54. Frazer I.Vaccines for papillomavirus infection.Virus Res,2002,89(2): 271-274.
55. Congilosi SM,Madoff RD. Current therapy for recurrent and extensive anal warts. Dis Colon Rectum, 1995,38:1101 - 1107.
56. Coleman N,Birley HD,Renton AM,et al.Immunological events in regressing genital warts.Am J Clin Pathol, 1994,102:768-774
57. Prummer O,Seyfarth C,Scherbaum WA,et al.Interferon-alpha antibodies in autoimmune diseases. J Interferon Res,1989,Suppl 1:S67-S74.
58. Jonasch E,Haluska FGInterferon in oncological practice: review of interferon biology, clinical applications, and toxicities.Oncologist, 2001,6(1):34-55.
59. Tracey L,Spiteri I,Ortiz P,et al.Transcriptional response of T cells to IFN-alpha: changes induced in IFN-alpha-sensitive and resistant cutaneous T cell lymphoma. J Interferon Cytokine Res,2004,24(3): 185-195.
60. van den Broek MF,Muller U,Huang S,et al.Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J Virol, 1995, 69(8):4792-4796.
61.Luft T,Luetjens P,Hochrein H,et al. IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int Immunol,2002 ,14(4):367-380.
62. Santini SM,Lapenta C,Logozzi M,et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med,2000, 191(10):1777-1788.
63. Radvanyi LQBanerjee A,Weir M,et al.Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells. Scand J Immunol, 1999,50(5):499-509.
64. Rogge L,Barberis-Maino L,Biffi M,et al.Selective expression of an interleukin-12 receptor component by human T helper 1 cells.J Exp Med. 1997,185(5):825-831.
65. Galun E,Zeira E,Pappo O,et al. Liver regeneration induced by a designer human IL-6/sIL-6R fusion protein reverses severe hepatocellular injury.FASEB J,2000,14(13): 1979-1987.
66. Bruno E,Briddell RA,Cooper RJ,et al.Recombinant GM-CSF/IL-3 fusion protein: its effect on in vitro human megakaryocytopoiesis.Exp Hematol, 1992,20(4):494-499.
67. O'Shaughnessy JA,Tolcher A,Riseberg D,et al.Prospective, randomized trial of 5-fluorouracil, leucovorin,doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer.Blood, 1996,87(6):2205-2211.
68．卿玉玲，赵嘉将，任红．乙型肝炎HBsAg和GM-CSF融合表达质粒的构建与表达．免疫学杂志，2003，19；201-204．
69. Xue F, Gu Z,Feng JA.LINKER: a web server to generate peptide sequences with extended conformation.Nucleic Acids Res,2004, 32:W562-W565.
70. Gustavsson M,Lehtio J,Denman S,et al.Stable linker peptides for a cellulose-binding domain-lipase fusion protein expressed in Pichia pastoris.Protein Eng,2001,14(9):711-715.
71. Cheah PL,Looi LM.Biology and pathological associations of the human papillomaviruses: a review.Malays J Pathol, 1998,20(1): 1-10.
72．鲁凤良，庄辉．核酸疫苗研究进展．中华预防医学杂志，1995，29(5)：303-304．
73. Tang DC,DeVit M,Johnston SA.Genetic immunization is a simple method for eliciting an immune response.Nature,1992,356(6365): 152-154.
74. Wolff JA,Malone RW, Williams P, et al.Direct gene transfer into mouse muscle in vivo. Science, 1990,247(4949 Pt1): 1465-1468.
75. Shroff KE,Smith LR, Baine Y, et al.Potential for plasmid DNAs as vaccines for the new millennium. Pharm. Sci. Technol, Today,1999, 2(5):205-212.
76. Hariharan MJ,Driver DA,Townsend K,et al. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol,1998,72(2):950-958.
77. Kirnbauer R, Taub J,Greenstone H,et al.Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles.J Virol, 1993,67(12):6929-6936.
78. Moniz M,Ling M,Hung CF,et al.HPV DNA vaccines.Front Biosci, 2003,8:d55-d68.
79. Brown MG,Scalzo AA,Matsumoto K,et al.The natural killer gene complex: a genetic basis for understanding natural killer cell function and innate immunity.Immunol Rev, 1997,155:53-65.
80．李振，曾耀英，蔡小嫦，等．不同病程尖锐湿疣患者外周血TH细胞亚群的研究．中华皮肤科杂志，2003，36(5)：253．
81. Wolff JA,Malone RW,Williams P,et al.Direct gene transfer into mouse muscle in vivo.Science, 1990,247(4949 Pt1): 1465-1468.
82. Tang DC,DeVit M,Johnston SA.Genetic immunization is a simple method for eliciting an immune response.Nature,1992,356(6365): 152-154.
83. Chow YH,Huang WL,Chi WK,et al.Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2.J Virol, 1997,71 (1): 169-178.
84. Larsen DL,Dybdahl-Sissoko N,McGregor MW, et al.Coadministration of DNA encoding interleukin-6 and hemagglutinin confers protection from influenza virus challenge in mice.J Virol, 1998,72(2): 1704-1708.
85. Kim JJ,Trivedi NN,Nottingham LK,et al.Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens.Eur J Immunol, 1998,28(3): 1089-1103.
86. Xin KQ,Hamajima K, Sasaki S,et al.Intranasal administration of human immunodeficiency virus type-1 ( HIV-1 ) DNA vaccine with interleukin-2 expression plasmid enhances cell mediated immunity against HIV-1. Immunology, 1998 ,94 (3):438-444.
87. Gherardi MM,Ramirez JC, Esteban M.Towards a new generation of vaccine : the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens.Histol Histopathol,2001,16 (2) :655-667.
88. Tsuji T,Hamajima K,Fukkushima J,et al.Enhancement of cell mediated immunity against HIV-1 induced by coinoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12. J Immunol ,1997,158 (8): 4008-4013.
89. Operschall E,Schuh T,Heinzerling L,et al.Enhanced protection against viral infection by co-administ ration of plasmid DNA coding for viral antigen and cytokines in mice. J Clin Virol, 1999 ,12(1-2): 17-27.
90. Lee SW,Cho J H, Sung YC.Optimal induction of hepatitis C virus envelope-specific immunity by bicist ronic plasmid DNA inoculation with the GM-CSF gene.J Virol ,1998,72 (10) :8430-8436.
91. Sin JI,Kim JJ,Ugen KE,et al.Enhancement of protective humoral ( Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of GM-CSF expression cassettes.Eur J Immunol, 1998,28 ( 11) :3530-3540.
92. Kim JJ,Yang JS,Montaner ,et al. Coimmunization with IFN-gamma or IL-2,but not IL-13 or IL-4 Cdna can enhance Th1-type DNA vaccine-induced immune response in vivo.J Interferon Cytokine Res,2000,20(3):311-319.
93. Kim JJ,Yang JS,Manson KH,et al . Modulation of anti-gen-specific cellular immune response to DNA vaccination in rhesus macaques through the use of IL-12,IFN-gamma,or IL-4 gene adjuvants . Vaccine,2001,19(17-19):2496-2505.
94. Iida T,Kuwata T,Ui M,et al.Augmentation of antigen-specific cytokine responses in the early phase of vaccination with a live-attenuated simian/human immunodeficiency chimeric virus expressing IFN-gamma. Arch Virol,2004,149:743-757.
95. McCormick AL,Thomas MS,Heath AW.Immunization with an interferon-gamma-gp120 fusion protein induces enhanced immune responses to human immunodeficiency virus gp120.J Infect Dis,2001,184:1423-1430.
96. Galvin TA,Muller J,Khan AS. Effect of different promoters on immune responses elicited by HIV-1 gag/env multigenic DNA vaccine in Macaca mulatta and Macaca nemestrina.Vaccine, 2000,18(23):2566-2583.
97. Montgomery DL,Shiver JW, Leander KR,et al.Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNACell Biol,1993 ,12(9):777-783.
98. Fynan EF,Webster RG, Fuller DH,et al.DNA vaccines:protective immunizations by parenteral,mucosal,and gene-gun inoculations.Proc NatlAcadSciUSA,1993,90(24):11478-11482.
99. Williams NA,Hirst TR,Nashar TO.Immune modulation by the cholera-like enterotoxins:from adjuvant to therapeutic. Immunol Today, 1999 ,20(2):95-101.
100. Singh M,Vajdy M,Gardner J,et al.Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. Vaccine,2001,20(3-4):594-602.
101. Shroff KE,Smith LR,Baine Y,et al.Potential for plasmid DNAs as vaccines for the new millennium. Pharm. Sci. Technol. Today, 1999,2(5):205-212.
102. Swain WE,Heydenburg Fuller D,Wu MS,et al.Tolerability and immune responses in humans to a PowderJect DNA vaccine for hepatitis B.Dev Biol (Basel),2000,104:115-119.
103. Giese M,Bahr U, Jakob NJ,et al. Stable and long-lasting immune response in horses after DNA vaccination against equine arteritis virus. Virus Genes,2002 ,25(2): 159-167.
104. De Rose R,Tennent J,McWaters P,et al. Efficacy of DNA vaccination by different routes of immunisation in sheep.Vet Immunol Immunopathol, 2002 ,90(1-2):55-63.
105. Cafaro A,Titti F,Fracasso C,et al.Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).Vaccine,2001,19(20-22):2862-2877.
106. Hoffman SL,Doolan DL.Can malaria DNA vaccines on their own be as immunogenic and protective as prime-boost approaches to immunization? Dev Biol (Basel),2000,104:121-132.
107. Shurshalina AV,Veryasov VN,Sukhikh GT.The ratio of cytokine levels in genital herpes during various phases of infection.Bull Exp Biol Med,2001,132(1):660-662.
108. El-Sherif AM,Seth R,Tighe PJ,et al.Quantitative analysis of IL-10 and IFN-gamma mRNA levels in normal cervix and human papillomavirus type 16 associated cervical precancer.J Pathol,2001,195(2):179-185.
109. Hsu KF,Hung CF,Cheng WF,et al. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther,2001 ,8(5):376-383.
110. Liu DW,Tsao YP,Kung JT,et al.Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.J Virol,2000 ,74(6):2888-2894.
111. Chen CH,Wang TL,Hung CF,et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene.Cancer Res,2000 ,60(4): 1035-1042.
112. Trimble C,Lin CT,Hung CF,et al.Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine,2003,21(25-26):4036-4042.
1. Searle PF, Mautner V.Adenoviral Vectors:not to be sneezed at.Gene Ther, 1998,5(6):725.
2. Shinoura N, Satou R, Yashida Y, et al.Adenorirus-mediated transfer of Bcl-x(L) protects neuronal cell from Bax-induced apoptosis.Exp Cell Res,2000,254(2): 221-231.
3. Nielsen LL,Gumani M, Syed J,et al.Recombinant E1-deleted adenovirus mediated gene therapy for cancer efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.Hum Gene Ther, 1998, 9(5):681-694.
4. Matsuoka N,Yukawa H,Ishii K,et al.Adenovirus-mediated gene transfer of Bcl-xL prevent cell death in primary neuronal culture of the rat .Neurosci Lett, 1999,270(3): 177-180
5. Sayegh MH.Finally, CTLA4Ig graduates to the clinic.J Clin Invest, 1999, 103(9):1223-1225.
6. Linsley, P.S.,et al.Human B7-1(CD80)and B7-2(CD86)bind with similar avidities but distinct kinetis to CD28 and CTLA-4 receptors. Immunity, 1994,1:793-801
7. Mihara M,Tan I,Chuzhin Y,et al.CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus.J clin Invest, 2000,106(1): 91-101.
8. Takiguchi M,Murakami M,Nakagawa I,et al.CTLA4IgG gene delivery prevents autoantibody production and lupus nephritis in MRL/lpr mice.Life Sci,2000,66( 11 ):991 -1001.
9. Peter I,Graf C,Dummer R,et al.A novel attenuated replication-competent adenovirus for melanoma therapy. Gene ther,2003,10(7): 530-539.
10. Sauter ER,Takemoto R,Litwin S,et al.P53 alone or in combination with antisense cyclinDl induces apoptosis and reduces tumor size in human melanoma.Cancer Gene Ther,2002,9(10):807-812.
11.Okada Y,Okada N,Nakagawa S,et al.Fiber-mutant technique can augment gene transduction efficacy and anti-tumor effect against established murine melanoma by cytokine-gene therapy using adenovirus vectors.Cancer Lett, 2002,177(1):57-63.
12. Koh TY,Park SW,Park KH,et al.Inhibitory effect of p27KIP1 gene transfer on head and neck Squamous cell carcinoma cell lines.Head Neck, 2003,25(1): 44-49.
13. O'Malley BW Jr,Li D,Carney J,et al.Molecular disruption of the MRN(95) complex inducesradiation sensitivity in head and neck cancer. Laryngoscope,2003,113(9): 1588-1594.
14. Shiver JW,Fu TM,Chen L,et al.Replication- imcompetent adenoviral vaccine vector elicitseffective antiimmunodeficiency-virus immunity. Nature,2002,415(6869): 331-335
15.Danilo R.Casimiro,Ling Chen,Tong-Ming Fu,et al.Compartive immunogenicity in RhesusMonkeys of DNA plasmid,Recombinant vaccinia Virus,and Replication-Defective Adenovirus Vectors Expressing a human Immunodeficiency virus Type 1 gag Gene.J virol,2003,77(11):6305-6313.
16. Barouch DH, Mckay PF,Sumida SM,et al.Plasmid Chemokines and Colony-Stimulating Factors Enhance the Immunogenicity of DNA Priming-Viral Vector Boosting Human Immunodeficiency Virus Type 1 vaccinesJ virol,2003,77(16):8729-8735.
17. Barouch,DH,Santra S,Tenner-Racz S,et al.Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA Vaccine expressing gpl20 and GM-CSF. J Immunol,2002,168:562-568.
18. Sedegah M,Weiss W,Sacci JB Jr,et al.Improving protective immunity induced by DNA-based immunization:priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus.J Immumol,2000,164:5905- 5912.
19. Nan x,Peng B,Hahn TW,et al.Development of an Ad7 cosmid system and generation of an Ad7deltaE1deltaE3HIV(MN) env/rev recombinant virus.Gene Ther,2003,10(4)326-336.
20. Patterson LJ,Prince GA,Richardson E,et al.Insertion of HIV-1 genes into Ad4DeltaE3 vector abrogates increased pathogenesis in cotton rats due to E3 deletion. Virology,2002,292(1): 107-113.
21. Takahashi H,Honma M,Ishida-Yamamoto A,et al.In vitro and in vivo transfer of Bcl-2 gene into keratinocytes suppresses UVB-induced apoptosis. Photochem photobiol,2001,74(4):579-586.
22. Kuroki T,Kashiwagi M,Ishino K,et al.Adenovirus-mediated gene transfer to keratinocytes-a review.J Investig Dermatol symp Proc.l999,4(2):153-157.
23. Liu Dw, Tsao YP,Hsieh CH,et al.Induction of CD8 T cells by Vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth.J virol,2000,74(19):9083-9089.
24. Brandsman JL,Shlyankevich M,Zhang L,et al.Vaccination of Rabbits with an Adenovirus vector Expressing the Papillomavirus E2 Protein Leads to Clearance of Papillomas and infection.J virol,2004,78(1): 116-123.
2．徐文严．STD预防与治疗．上海第二军医大学出版社，2001，23-35．
3．邵长庚．我国性病的防治状况及其对策．中华皮肤科杂志，1993，26(3)：131．
4．全国艾滋病性病防治协作组．1999年性病流行病学分析，中国性病艾滋病防治，2000，6(3)129-140．
5. Hoyme UB,Hagedorn M,Schindler AE,et al.Effect of adjuvant imiquimod 5% cream on sustained clearance of anogenital warts following laser treatment.Infect Dis Obstet Gynecol,2002,10(2): 79-88.
6．王俊杰，杨军，谢卫红等．5％咪喹莫特预防尖锐湿疣复发的临床疗效观察，临床皮肤科杂志，2005，34(6)：404．
7．金泓，邓列华，谢明等．重组人a-2b干扰素凝胶联合高频电灼术治疗尖锐湿疣临床观察．临床皮肤科杂志，2005，34(2)：124-125．
8. Stanley MA.Immunobiology of papillomavirus infections.J Reprod Immunol,2001,52(1-2) :45-59.
9. Wyllie FS,Haughton MF,Rowson JM,et al.Human thyroid cancer cells as a source of iso-genic,iso-phenotypic cell lines with or without functional p53.Br J Cancer,1999,79(7-8): 1111-1120.
10. Butz K,Whitaker N,Denk C,et al.Induction of the p53-target gene GADD45 in HPV-positive cancer cells. Oncogene,1999,18(14): 2381-2386.
11. Phillips AC,Vousden KH. Analysis of the interaction between human papillomavirus type 16 E7 and the TATA-binding protein,TBP.J Gen Virol, 1997,78 ( Pt 4):905-909.
12. Cornelison TL.Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment.Curr OpinOncol,2000, 12(5):466-473.
13. de Villiers EM.Human papillomavirus infections in skin cancers. Biomed Pharmacother, 1998,52( 1 ):26-33.
14. Yoneta A,Yamashita T,Jin HY,et al.Development of squamous cell carcinoma by two high-risk human papillomaviruses (HPVs), a novel HPV-67 and HPV-31 from bowenoid papulosis.Br J Dermatol,2000, 143(3):604-608.
15. Marshall K.Cervical dysplasia:early intervention.Altern Med Rev, 2003,8(2):156-170.
16. Munoz N,Bosch FX,de Sanjose S,et al.Epidemiologic classification of human papillomavirus types associated with cervical cancer.N Engl J Med,2003,348(6):518-527.
17. Rice PS,Mant C,Cason J,et al.High prevalence of human papillomavirus type 16 infection among children.J Med Virol,2000,61(1):70-75.
18．洪少林，王家璧，李平川．尖锐湿疣病变的人乳头瘤病毒6型L1序列多态性分析．病毒学报，2002，18(2)：102-107．
19．蒋明军，王书崎，龚向东等．尖锐湿疣皮损中人乳头瘤病毒基因分型研究．中华皮肤科杂志，2005，38(5)：262-264．
20. Bercovich JA,Centeno CR, Aguilar OG,et al.Presence and integration of human papillomavirus type 6 in a tonsillar carcinoma.J Gen Virol, 1991,72 (Pt 10):2569-2572.
21. Boshart M,zur Hausen H.Human papillomaviruses in Buschke-Lowenstein tumors: physical state of the DNA and identification of a tandem duplication in the noncoding region of a human papillomavirus6 subtype. J Virol, 1986,58(3):963-966.
22. DiLorenzo TP, Tamsen A, Abramson AL, et al.Human papillomavirus type 6a DNA in the lung carcinoma of a patient with recurrent laryngeal papillomatosis is characterized by a partial duplication.J Gen Virol,1992,73 (Pt 2):423-428.
23. Barbosa MS,Edmonds C,Fisher C,et al. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase Ⅱ phosphorylation.EMBO J, 1990,9(1): 153-160.
24. Munger K,Yee CL,Phelps WC,et al.Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences.J Virol, 1991,65(7):3943-3948.
25．白海燕，章静波．首例癌症疫苗即将面世，基础医学与临床，2005，25(3)：252．
26. O'Brien PM, Saveria Campo M.Evasion of host immunity directed by papillomavirus-encoded proteins. Virus Res,2002,88(1-2): 103-117.
27. Ferenczy A, Coutlee F, Franco E, et al.Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments. CMAJ,2003,169(5):431-434.
28. Stockfleth E,Nindl I,Sterry W, et al.Human papillomaviruses in transplant-associated skin cancers. Dermatol Surg,2004,30:604-609.
29. Chen Z,Kamath P, Zhang S,et al.Effects on tumor cells of ribozymes that cleave the RNA transcripts of human papillomavirus type 18. Cancer Gene Ther, 1996,3 (1): 18-23.
30. Clawson GA,Miranda GQ, Sivarajah A,et al.Inhibition of papilloma progression by antisense oligonucleotides targeted to HPV11 E6/E7 RNA. Gene Ther,2004,11 (17): 1331-1341.
31. Butz K, Ristriani T, Hengstermann A,et al.siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene,2003,22(38):5938-5945.
32. Oh TJ,Kim CJ,Woo SK,et al.Development and clinical evaluation of a highly sensitive DNA microarray for detection and genotyping of human papillomaviruses. J Clin Microbiol,2004,42(7):3272-3280.
33. Molijn A,Kleter B,Quint W,et al.Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol,2005,32 Suppl 1:S43-S51.
34. Meyer T,Arndt R,Christophers E,et al.Importance of human papillomaviruses for the development of skin cancer. Cancer Detect Prev,2001,25(6):533-547.
35. Ha PK,Califano JA.The role of human papillomavirus in oral carcinogenesis.Crit Rev Oral Biol Med,2004,15(4): 188-196.
36. Bouda M, Gorgoulis VG, Kastrinakis NG, et al. "High risk" HPV types are frequently detected in potentially malignant and malignant oral lesions, but not in normal oral mucosa. Mod Pathol,2000,13:644-653.
37. Brandsma JL,Abramson AL. Association of papillomavirus with cancers of the head and neck.Arch Otolaryngol Head Neck Surg, 1989,115:621-625.
38. Dreau D,Culberson C,Wyatt S,et al.Human papilloma virus in melanoma biopsy specimens and its relation to melanoma progression. Ann Surg,2000,231(5):664-671.
39. Favre M,Orth G, Majewski S,et al.Psoriasis:A possible reservoir for human papillomavirus type 5, the virus associated with skin carcinomas of epidermodysplasia verruciformis. J Invest Dermatol, 1998,110(4):311-317.
40. Handsfield HH.Clinical presentation and natural course of anogenital warts.Am J Med, 1997,102(5A): 16-20.
41. Fierlbeck G,Schiebel U, Muller C.Immunohistology of genital warts in different stages of regression after therapy with interferon gamma.Dermatologica, 1989,179(4): 191-195.
42. Ling M,Kanayama M,Roden R,et al.Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers.J Biomed Sci,2000,7(5):341-356.
43．刘方，王家璧．人乳头瘤病毒疫苗研究的新进展，中国艾滋病性病，2003，9(3)：182-184．
44. Fierlbeck G, Breuninger H,Fierlbeck B,et al.Condylomata acuminatatopical and systemic interferon therapy.Hautarzt, 1991,42(1):39-43.
45. Berry JM,Palefsky JM.A review of human papillomavirus vaccines: from basic science to clinical trials. Front Biosci,2003,8:s333-345.
46. Frazer I.Vaccines for papillomavirus infection.Virus Res,2002,89(2): 271-274.
47. Tobery TW,Smith JF, Kuklin N,et al.Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cellmediated immune responses in immunized rhesus macaques. Vaccine,2003,21 (13-14): 1539-1547.
48. Meschede W,Zumbach K,Braspenning J,et al.Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer.J Clin Microbiol, 1998,36(2):475-480.
49．党育平，王刚，范雪莉等．人乳头瘤病毒6型E7与结核杆菌热休克蛋白70融合基因的构建及原核表达．临床皮肤科杂志，2005，34(4)：208-210．
50. De Bruijn ML,Greenstone HL,Vermeulen H,et,al.L1-specific protection from tumor challenge elicited by HPV16 virus-like particles.Virology, 1998,250(2):371-376.
51. Sarkar AK,Tortolero-Luna G,Nehete PN,et al.Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16.Viral Immunol, 1995,8(3): 165-174.
52．骆卫峰，韩立群，任皎，等．人乳头瘤病毒16型E6和E7基因及其突变体转化活性的研究．病毒学报，2002，18：97-101．
53. Steller MA.Cervical cancer vaccines:progress and prospects.J Soc Gynecol Investig,2002,9(5):254-264.
54. Frazer I.Vaccines for papillomavirus infection.Virus Res,2002,89(2): 271-274.
55. Congilosi SM,Madoff RD. Current therapy for recurrent and extensive anal warts. Dis Colon Rectum, 1995,38:1101 - 1107.
56. Coleman N,Birley HD,Renton AM,et al.Immunological events in regressing genital warts.Am J Clin Pathol, 1994,102:768-774
57. Prummer O,Seyfarth C,Scherbaum WA,et al.Interferon-alpha antibodies in autoimmune diseases. J Interferon Res,1989,Suppl 1:S67-S74.
58. Jonasch E,Haluska FGInterferon in oncological practice: review of interferon biology, clinical applications, and toxicities.Oncologist, 2001,6(1):34-55.
59. Tracey L,Spiteri I,Ortiz P,et al.Transcriptional response of T cells to IFN-alpha: changes induced in IFN-alpha-sensitive and resistant cutaneous T cell lymphoma. J Interferon Cytokine Res,2004,24(3): 185-195.
60. van den Broek MF,Muller U,Huang S,et al.Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J Virol, 1995, 69(8):4792-4796.
61.Luft T,Luetjens P,Hochrein H,et al. IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int Immunol,2002 ,14(4):367-380.
62. Santini SM,Lapenta C,Logozzi M,et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med,2000, 191(10):1777-1788.
63. Radvanyi LQBanerjee A,Weir M,et al.Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells. Scand J Immunol, 1999,50(5):499-509.
64. Rogge L,Barberis-Maino L,Biffi M,et al.Selective expression of an interleukin-12 receptor component by human T helper 1 cells.J Exp Med. 1997,185(5):825-831.
65. Galun E,Zeira E,Pappo O,et al. Liver regeneration induced by a designer human IL-6/sIL-6R fusion protein reverses severe hepatocellular injury.FASEB J,2000,14(13): 1979-1987.
66. Bruno E,Briddell RA,Cooper RJ,et al.Recombinant GM-CSF/IL-3 fusion protein: its effect on in vitro human megakaryocytopoiesis.Exp Hematol, 1992,20(4):494-499.
67. O'Shaughnessy JA,Tolcher A,Riseberg D,et al.Prospective, randomized trial of 5-fluorouracil, leucovorin,doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer.Blood, 1996,87(6):2205-2211.
68．卿玉玲，赵嘉将，任红．乙型肝炎HBsAg和GM-CSF融合表达质粒的构建与表达．免疫学杂志，2003，19；201-204．
69. Xue F, Gu Z,Feng JA.LINKER: a web server to generate peptide sequences with extended conformation.Nucleic Acids Res,2004, 32:W562-W565.
70. Gustavsson M,Lehtio J,Denman S,et al.Stable linker peptides for a cellulose-binding domain-lipase fusion protein expressed in Pichia pastoris.Protein Eng,2001,14(9):711-715.
71. Cheah PL,Looi LM.Biology and pathological associations of the human papillomaviruses: a review.Malays J Pathol, 1998,20(1): 1-10.
72．鲁凤良，庄辉．核酸疫苗研究进展．中华预防医学杂志，1995，29(5)：303-304．
73. Tang DC,DeVit M,Johnston SA.Genetic immunization is a simple method for eliciting an immune response.Nature,1992,356(6365): 152-154.
74. Wolff JA,Malone RW, Williams P, et al.Direct gene transfer into mouse muscle in vivo. Science, 1990,247(4949 Pt1): 1465-1468.
75. Shroff KE,Smith LR, Baine Y, et al.Potential for plasmid DNAs as vaccines for the new millennium. Pharm. Sci. Technol, Today,1999, 2(5):205-212.
76. Hariharan MJ,Driver DA,Townsend K,et al. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol,1998,72(2):950-958.
77. Kirnbauer R, Taub J,Greenstone H,et al.Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles.J Virol, 1993,67(12):6929-6936.
78. Moniz M,Ling M,Hung CF,et al.HPV DNA vaccines.Front Biosci, 2003,8:d55-d68.
79. Brown MG,Scalzo AA,Matsumoto K,et al.The natural killer gene complex: a genetic basis for understanding natural killer cell function and innate immunity.Immunol Rev, 1997,155:53-65.
80．李振，曾耀英，蔡小嫦，等．不同病程尖锐湿疣患者外周血TH细胞亚群的研究．中华皮肤科杂志，2003，36(5)：253．
81. Wolff JA,Malone RW,Williams P,et al.Direct gene transfer into mouse muscle in vivo.Science, 1990,247(4949 Pt1): 1465-1468.
82. Tang DC,DeVit M,Johnston SA.Genetic immunization is a simple method for eliciting an immune response.Nature,1992,356(6365): 152-154.
83. Chow YH,Huang WL,Chi WK,et al.Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2.J Virol, 1997,71 (1): 169-178.
84. Larsen DL,Dybdahl-Sissoko N,McGregor MW, et al.Coadministration of DNA encoding interleukin-6 and hemagglutinin confers protection from influenza virus challenge in mice.J Virol, 1998,72(2): 1704-1708.
85. Kim JJ,Trivedi NN,Nottingham LK,et al.Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens.Eur J Immunol, 1998,28(3): 1089-1103.
86. Xin KQ,Hamajima K, Sasaki S,et al.Intranasal administration of human immunodeficiency virus type-1 ( HIV-1 ) DNA vaccine with interleukin-2 expression plasmid enhances cell mediated immunity against HIV-1. Immunology, 1998 ,94 (3):438-444.
87. Gherardi MM,Ramirez JC, Esteban M.Towards a new generation of vaccine : the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens.Histol Histopathol,2001,16 (2) :655-667.
88. Tsuji T,Hamajima K,Fukkushima J,et al.Enhancement of cell mediated immunity against HIV-1 induced by coinoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12. J Immunol ,1997,158 (8): 4008-4013.
89. Operschall E,Schuh T,Heinzerling L,et al.Enhanced protection against viral infection by co-administ ration of plasmid DNA coding for viral antigen and cytokines in mice. J Clin Virol, 1999 ,12(1-2): 17-27.
90. Lee SW,Cho J H, Sung YC.Optimal induction of hepatitis C virus envelope-specific immunity by bicist ronic plasmid DNA inoculation with the GM-CSF gene.J Virol ,1998,72 (10) :8430-8436.
91. Sin JI,Kim JJ,Ugen KE,et al.Enhancement of protective humoral ( Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of GM-CSF expression cassettes.Eur J Immunol, 1998,28 ( 11) :3530-3540.
92. Kim JJ,Yang JS,Montaner ,et al. Coimmunization with IFN-gamma or IL-2,but not IL-13 or IL-4 Cdna can enhance Th1-type DNA vaccine-induced immune response in vivo.J Interferon Cytokine Res,2000,20(3):311-319.
93. Kim JJ,Yang JS,Manson KH,et al . Modulation of anti-gen-specific cellular immune response to DNA vaccination in rhesus macaques through the use of IL-12,IFN-gamma,or IL-4 gene adjuvants . Vaccine,2001,19(17-19):2496-2505.
94. Iida T,Kuwata T,Ui M,et al.Augmentation of antigen-specific cytokine responses in the early phase of vaccination with a live-attenuated simian/human immunodeficiency chimeric virus expressing IFN-gamma. Arch Virol,2004,149:743-757.
95. McCormick AL,Thomas MS,Heath AW.Immunization with an interferon-gamma-gp120 fusion protein induces enhanced immune responses to human immunodeficiency virus gp120.J Infect Dis,2001,184:1423-1430.
96. Galvin TA,Muller J,Khan AS. Effect of different promoters on immune responses elicited by HIV-1 gag/env multigenic DNA vaccine in Macaca mulatta and Macaca nemestrina.Vaccine, 2000,18(23):2566-2583.
97. Montgomery DL,Shiver JW, Leander KR,et al.Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNACell Biol,1993 ,12(9):777-783.
98. Fynan EF,Webster RG, Fuller DH,et al.DNA vaccines:protective immunizations by parenteral,mucosal,and gene-gun inoculations.Proc NatlAcadSciUSA,1993,90(24):11478-11482.
99. Williams NA,Hirst TR,Nashar TO.Immune modulation by the cholera-like enterotoxins:from adjuvant to therapeutic. Immunol Today, 1999 ,20(2):95-101.
100. Singh M,Vajdy M,Gardner J,et al.Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. Vaccine,2001,20(3-4):594-602.
101. Shroff KE,Smith LR,Baine Y,et al.Potential for plasmid DNAs as vaccines for the new millennium. Pharm. Sci. Technol. Today, 1999,2(5):205-212.
102. Swain WE,Heydenburg Fuller D,Wu MS,et al.Tolerability and immune responses in humans to a PowderJect DNA vaccine for hepatitis B.Dev Biol (Basel),2000,104:115-119.
103. Giese M,Bahr U, Jakob NJ,et al. Stable and long-lasting immune response in horses after DNA vaccination against equine arteritis virus. Virus Genes,2002 ,25(2): 159-167.
104. De Rose R,Tennent J,McWaters P,et al. Efficacy of DNA vaccination by different routes of immunisation in sheep.Vet Immunol Immunopathol, 2002 ,90(1-2):55-63.
105. Cafaro A,Titti F,Fracasso C,et al.Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).Vaccine,2001,19(20-22):2862-2877.
106. Hoffman SL,Doolan DL.Can malaria DNA vaccines on their own be as immunogenic and protective as prime-boost approaches to immunization? Dev Biol (Basel),2000,104:121-132.
107. Shurshalina AV,Veryasov VN,Sukhikh GT.The ratio of cytokine levels in genital herpes during various phases of infection.Bull Exp Biol Med,2001,132(1):660-662.
108. El-Sherif AM,Seth R,Tighe PJ,et al.Quantitative analysis of IL-10 and IFN-gamma mRNA levels in normal cervix and human papillomavirus type 16 associated cervical precancer.J Pathol,2001,195(2):179-185.
109. Hsu KF,Hung CF,Cheng WF,et al. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther,2001 ,8(5):376-383.
110. Liu DW,Tsao YP,Kung JT,et al.Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.J Virol,2000 ,74(6):2888-2894.
111. Chen CH,Wang TL,Hung CF,et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene.Cancer Res,2000 ,60(4): 1035-1042.
112. Trimble C,Lin CT,Hung CF,et al.Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine,2003,21(25-26):4036-4042.
1. Searle PF, Mautner V.Adenoviral Vectors:not to be sneezed at.Gene Ther, 1998,5(6):725.
2. Shinoura N, Satou R, Yashida Y, et al.Adenorirus-mediated transfer of Bcl-x(L) protects neuronal cell from Bax-induced apoptosis.Exp Cell Res,2000,254(2): 221-231.
3. Nielsen LL,Gumani M, Syed J,et al.Recombinant E1-deleted adenovirus mediated gene therapy for cancer efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.Hum Gene Ther, 1998, 9(5):681-694.
4. Matsuoka N,Yukawa H,Ishii K,et al.Adenovirus-mediated gene transfer of Bcl-xL prevent cell death in primary neuronal culture of the rat .Neurosci Lett, 1999,270(3): 177-180
5. Sayegh MH.Finally, CTLA4Ig graduates to the clinic.J Clin Invest, 1999, 103(9):1223-1225.
6. Linsley, P.S.,et al.Human B7-1(CD80)and B7-2(CD86)bind with similar avidities but distinct kinetis to CD28 and CTLA-4 receptors. Immunity, 1994,1:793-801
7. Mihara M,Tan I,Chuzhin Y,et al.CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus.J clin Invest, 2000,106(1): 91-101.
8. Takiguchi M,Murakami M,Nakagawa I,et al.CTLA4IgG gene delivery prevents autoantibody production and lupus nephritis in MRL/lpr mice.Life Sci,2000,66( 11 ):991 -1001.
9. Peter I,Graf C,Dummer R,et al.A novel attenuated replication-competent adenovirus for melanoma therapy. Gene ther,2003,10(7): 530-539.
10. Sauter ER,Takemoto R,Litwin S,et al.P53 alone or in combination with antisense cyclinDl induces apoptosis and reduces tumor size in human melanoma.Cancer Gene Ther,2002,9(10):807-812.
11.Okada Y,Okada N,Nakagawa S,et al.Fiber-mutant technique can augment gene transduction efficacy and anti-tumor effect against established murine melanoma by cytokine-gene therapy using adenovirus vectors.Cancer Lett, 2002,177(1):57-63.
12. Koh TY,Park SW,Park KH,et al.Inhibitory effect of p27KIP1 gene transfer on head and neck Squamous cell carcinoma cell lines.Head Neck, 2003,25(1): 44-49.
13. O'Malley BW Jr,Li D,Carney J,et al.Molecular disruption of the MRN(95) complex inducesradiation sensitivity in head and neck cancer. Laryngoscope,2003,113(9): 1588-1594.
14. Shiver JW,Fu TM,Chen L,et al.Replication- imcompetent adenoviral vaccine vector elicitseffective antiimmunodeficiency-virus immunity. Nature,2002,415(6869): 331-335
15.Danilo R.Casimiro,Ling Chen,Tong-Ming Fu,et al.Compartive immunogenicity in RhesusMonkeys of DNA plasmid,Recombinant vaccinia Virus,and Replication-Defective Adenovirus Vectors Expressing a human Immunodeficiency virus Type 1 gag Gene.J virol,2003,77(11):6305-6313.
16. Barouch DH, Mckay PF,Sumida SM,et al.Plasmid Chemokines and Colony-Stimulating Factors Enhance the Immunogenicity of DNA Priming-Viral Vector Boosting Human Immunodeficiency Virus Type 1 vaccinesJ virol,2003,77(16):8729-8735.
17. Barouch,DH,Santra S,Tenner-Racz S,et al.Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA Vaccine expressing gpl20 and GM-CSF. J Immunol,2002,168:562-568.
18. Sedegah M,Weiss W,Sacci JB Jr,et al.Improving protective immunity induced by DNA-based immunization:priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus.J Immumol,2000,164:5905- 5912.
19. Nan x,Peng B,Hahn TW,et al.Development of an Ad7 cosmid system and generation of an Ad7deltaE1deltaE3HIV(MN) env/rev recombinant virus.Gene Ther,2003,10(4)326-336.
20. Patterson LJ,Prince GA,Richardson E,et al.Insertion of HIV-1 genes into Ad4DeltaE3 vector abrogates increased pathogenesis in cotton rats due to E3 deletion. Virology,2002,292(1): 107-113.
21. Takahashi H,Honma M,Ishida-Yamamoto A,et al.In vitro and in vivo transfer of Bcl-2 gene into keratinocytes suppresses UVB-induced apoptosis. Photochem photobiol,2001,74(4):579-586.
22. Kuroki T,Kashiwagi M,Ishino K,et al.Adenovirus-mediated gene transfer to keratinocytes-a review.J Investig Dermatol symp Proc.l999,4(2):153-157.
23. Liu Dw, Tsao YP,Hsieh CH,et al.Induction of CD8 T cells by Vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth.J virol,2000,74(19):9083-9089.
24. Brandsman JL,Shlyankevich M,Zhang L,et al.Vaccination of Rabbits with an Adenovirus vector Expressing the Papillomavirus E2 Protein Leads to Clearance of Papillomas and infection.J virol,2004,78(1): 116-123.